Related references
Note: Only part of the references are listed.Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
Y. K. Onno Teng et al.
BMJ OPEN (2019)
Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting
C. Anjo et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2019)
Rebalancing Immune Homeostasis to Treat Autoimmune Diseases
David A. Horwitz et al.
TRENDS IN IMMUNOLOGY (2019)
B cell alterations during BAFF inhibition with belimumab in SLE
Daniel Ramskold et al.
EBIOMEDICINE (2019)
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis
Ho So et al.
CLINICAL RHEUMATOLOGY (2018)
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
Luca Iaccarino et al.
JOURNAL OF AUTOIMMUNITY (2018)
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus
Tineke Kraaij et al.
JOURNAL OF AUTOIMMUNITY (2018)
Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
Antonis Fanouriakis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis
Liliana Michelle Gomez Mendez et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Update on Lupus Nephritis
Salem Almaani et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus
Myles J. Lewis et al.
RHEUMATOLOGY (2017)
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus
Luca Iaccarino et al.
ARTHRITIS CARE & RESEARCH (2017)
Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases
C. Sjowall et al.
LUPUS (2017)
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre
Md Yuzaiful Md Yusof et al.
RHEUMATOLOGY (2017)
Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
Zahi Touma et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
Ioannis Parodis et al.
AUTOIMMUNITY REVIEWS (2017)
The frequency and outcome of lupus nephritis: results from an international inception cohort study
John G. Hanly et al.
RHEUMATOLOGY (2016)
Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review
Anne Contis et al.
CLINICAL RHEUMATOLOGY (2016)
Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
C. E. Collins et al.
LUPUS SCIENCE & MEDICINE (2016)
First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
Andreas Schwarting et al.
RHEUMATOLOGY AND THERAPY (2016)
Rituximab for IgG4-related disease: a prospective, open-label trial
Mollie N. Carruthers et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Tobias Alexander et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2015)
Rituximab for rheumatoid arthritis
Maria Angeles Lopez-Olivo et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
EVALUATION OF USE OF BELIMUMAB IN CLINICAL PRACTICE SETTINGS (OBSERVE STUDY) IN SPAIN: HEALTH RESOURCE UTILIZATION AND LABOUR ABSENTEEISM
J. Cortes et al.
VALUE IN HEALTH (2014)
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
Michelle A. Petri et al.
ARTHRITIS AND RHEUMATISM (2013)
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)
M. Witt et al.
LUPUS (2013)
CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation
Fabian Flores-Borja et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
William Stohl et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
A. Fernandez-Nebro et al.
LUPUS (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells
Yohei Iwata et al.
BLOOD (2011)
B Cell and BAFF Dependence of IFN-α-Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 Mice
Noam Jacob et al.
JOURNAL OF IMMUNOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Safety and Efficacy of Rituximab in Systemic Lupus Erythematosus
Benjamin Terrier et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF
Miyo Ota et al.
JOURNAL OF IMMUNOLOGY (2010)
Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB/W F1 Mice
Karen M. Haas et al.
JOURNAL OF IMMUNOLOGY (2010)
Regulatory B Cells (B10 Cells) Have a Suppressive Role in Murine Lupus: CD19 and B10 Cell Deficiency Exacerbates Systemic Autoimmunity
Rei Watanabe et al.
JOURNAL OF IMMUNOLOGY (2010)
Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients
M. Garcia-Carrasco et al.
LUPUS (2010)
Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus
Fausta Catapano et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Retrospective Seven-Year Analysis of the Use of B Cell Depletion Therapy in Systemic Lupus Erythematosus at University College London Hospital: The First Fifty Patients
Tim Y-T. Lu et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response
G. Cambridge et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus
Shaoqing Ju et al.
CLINICAL BIOCHEMISTRY (2006)
Ethnicity and mortality from systemic lupus erythematosus in the US
E. Krishnan et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
A role for BLyS in the activation of innate immune cells
Sock Kyung Chang et al.
BLOOD (2006)
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF
Chaim O. Jacob et al.
JOURNAL OF IMMUNOLOGY (2006)
Outcomes in African Americans and Hispanics with lupus nephritis
G. Contreras et al.
KIDNEY INTERNATIONAL (2006)
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - Relationships with B cell depletion, circulating antibodies, and clinical relapse
G Cambridge et al.
ARTHRITIS AND RHEUMATISM (2006)
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients
MJ Leandro et al.
RHEUMATOLOGY (2005)
Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus
A Cappione et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
JE Gottenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
BAFF augments certain Th1-associated inflammatory responses
APR Sutherland et al.
JOURNAL OF IMMUNOLOGY (2005)
Defective B cell tolerance checkpoints in systemic lupus erythematosus
S Yurasov et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF
R Lesley et al.
IMMUNITY (2004)
Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus
M Ramanujam et al.
JOURNAL OF IMMUNOLOGY (2004)
B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab
RJ Looney et al.
ARTHRITIS AND RHEUMATISM (2004)
Dysfunctional B cells in systemic lupus erythematosus
Y Renaudineau et al.
AUTOIMMUNITY REVIEWS (2004)
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches
M Thien et al.
IMMUNITY (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Development of autoantibodies before the clinical onset of systemic lupus erythematosus
MR Arbuckle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus - Longitudinal observations
W Stohl et al.
ARTHRITIS AND RHEUMATISM (2003)
An open study of B lymphocyte depletion in systemic lupus erythematosus
MJ Leandro et al.
ARTHRITIS AND RHEUMATISM (2002)
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2
N Kayagaki et al.
IMMUNITY (2002)
T cell costimulation by the TNF ligand BAFF
B Huard et al.
JOURNAL OF IMMUNOLOGY (2001)
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency
MH Yan et al.
CURRENT BIOLOGY (2001)
BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF
JS Thompson et al.
SCIENCE (2001)
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice
H Wang et al.
NATURE IMMUNOLOGY (2001)
Synthesis and release of B-lymphocyte stimulator from myeloid cells
B Nardelli et al.
BLOOD (2001)
TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation
XZ Xia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
JA Gross et al.
NATURE (2000)
Share Paper
